Pilot Study to Develop 3 Tesla MRI for Evaluation of Renal Tumors

Sponsor
M.D. Anderson Cancer Center (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT00507884
Collaborator
(none)
45
1
210
0.2

Study Details

Study Description

Brief Summary

The goal of this clinical research study is to find out if "3 Tesla" MRI is as good as CT scan in the evaluation of kidney tumor(s).

Objectives:

To provide preliminary data to enable subsequent development of an MRI protocol at 3 Tesla for evaluation of renal tumors and their vascular supply, which can be adopted in patients who are unable to undergo CT evaluation.

Condition or Disease Intervention/Treatment Phase
  • Procedure: 3 Tesla MRI Scan

Detailed Description

"3 Tesla" MRI is a new MRI scanner that in theory, can produce better images than currently available MRI scanners.

Currently, CT scanning is the main way of evaluating tumors in the kidneys. However, there are some patients who cannot have CT scans (usually, because of allergy to CT contrast medium or kidney damage/failure). It is with these patients that researchers are hoping to use a technique (using MRI) that is as good as CT scanning.

As part of your standard of care, your doctor is requesting a CT scan of your kidneys and abdomen. If you take part in this study, you will have a "3 Tesla" MRI scan of your kidneys and abdomen as well, within 15 days following your routine CT.

For the "3 Tesla" MRI scan, you will be lying flat on the MRI scanner, and as with a regular scan, you will have a small needle placed in a vein in your arm to inject the contrast dye. A diuretic, Lasix, will be given to help distend the internal tubes in the kidney to help view your kidney better. The MRI scan will take between 1-2 hours to perform. As with regular scans, you may be asked to hold your breath on occasions.

If there is a concern about your kidney function, blood (about 1 teaspoon) will be drawn to test your kidney function before you have the MRI.

Your participation in the study will be complete at the end of the MRI scan. The routine CT scan will be the main decision making examination. However, if the MRI shows something different and potentially relevant to your care, your referring physician will be informed.

This is an investigational study. A total of 45 patients will take part in this study. All will be enrolled at MD Anderson.

Study Design

Study Type:
Observational
Anticipated Enrollment :
45 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Pilot Study to Develop 3 Tesla MRI for Evaluation of Renal Tumors
Actual Study Start Date :
Mar 1, 2005
Anticipated Primary Completion Date :
Sep 1, 2022
Anticipated Study Completion Date :
Sep 1, 2022

Arms and Interventions

Arm Intervention/Treatment
3 Tesla MRI

Patients with renal tumors scheduled to have a CT scan of the kidneys and abdomen.

Procedure: 3 Tesla MRI Scan
MRI of the kidneys and abdomen to be done within 15 days following the routine CT and lasting 1 - 2 hours.

Outcome Measures

Primary Outcome Measures

  1. Comparison of CT and MRI scans of patients with renal cell carcinoma in evaluating each of nine imaging variables. [4 Years]

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Patients who have undergone or are due to undergo a CT Renal Protocol study, in the course of pre-operative evaluation for renal tumor surgery.

  2. Written informed consent will be obtained.

Exclusion Criteria:
  1. Patients with an allergy to both gadopentetate dimeglumine and gadodiamide MRI contrast agents.

  2. Patients with certain metallic implants, e.g., cardiac pacemakers, cardiac defibrillators, aneurysm clips, neurostimulators, and certain metallic foreign bodies. Implanted medical devices must be MRI compatible at 3.0 Tesla field strengths.

  3. Patients with claustrophobia, or requiring sedation for the MRI scan.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Texas MD Anderson Cancer Center Houston Texas United States 77030

Sponsors and Collaborators

  • M.D. Anderson Cancer Center

Investigators

  • Principal Investigator: Chaan Ng, MD, M.D. Anderson Cancer Center

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT00507884
Other Study ID Numbers:
  • 2004-0875
First Posted:
Jul 27, 2007
Last Update Posted:
Dec 31, 2020
Last Verified:
Dec 1, 2020
Keywords provided by M.D. Anderson Cancer Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 31, 2020